BRCA1 and ovarian cancer: For example, CCNE1 amplification/gain, which is a predictive biomarker of PARPi and platinum-based treatment resistance in epithelial ovarian cancers [151], is mutually exclusive with a pathogenic BRCA1/2 mutation in ovarian cancers [152].